Population distribution and effects on drug metabolism of a genetic variant in the 5' promotor region of CYP3A4

Clinical Pharmacology and Therapeutics

Volumn 66, Issue 3, 1999, Pages 288-294

  Ball, Simon E ^a   Scatina, JoAnn ^b   Kao, John ^b   Ferron, Geraldine M ^b   Fruncillo, Richard ^b   Mayer, Philip ^b   Weinryb, Ira ^b   Guida, Marco ^b   Hopkins, Penelope J ^b   Warner, Natalie ^b   Hall, Jeff ^b  

^a PFIZER INC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A4; CYTOCHROME P450 ISOENZYME; ERYTHROMYCIN; NIFEDIPINE; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; AREA UNDER THE CURVE; ARTICLE; CAUCASIAN; CHINESE; DEMETHYLATION; DRUG BLOOD LEVEL; DRUG METABOLISM; ETHNIC GROUP; GENE EXPRESSION; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NEGRO; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION;

AFRICAN CONTINENTAL ANCESTRY GROUP; AREA UNDER CURVE; ASIAN CONTINENTAL ANCESTRY GROUP; BREATH TESTS; CALCIUM CHANNEL BLOCKERS; CONTINENTAL POPULATION GROUPS; CYTOCHROME P-450 ENZYME SYSTEM; DNA PRIMERS; ERYTHROMYCIN; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENOTYPE; HISPANIC AMERICANS; HUMANS; MIXED FUNCTION OXYGENASES; NIFEDIPINE; PHENOTYPE; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS); PROTEIN SYNTHESIS INHIBITORS; REFERENCE VALUES;

EID: 0032825907     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(99)70037-8     Document Type: Article

References (31)

1. 1. Rendic S, Di Carlo FJ. Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers and inhibitors. Drug Metab Rev 1997;29: 413-580.
2. 2. Wrighton SA, Thomas PE, Willis P, Maines SL, Watkins PB, Levin W, et al. Purification of a human liver cytochrome P-450 immunochemically related to several cytochromes P-450 purified from untreated rats. J Clin Invest 1987;80:1017-22.
3. 3. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994;270:414-23.
4. 4. Guengerich FP, Martin MV, Beaune PH, Kremers P, Wolff T, Waxman DJ. Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. J Biol Chem 1986; 261:5051-60.
5. 5. Kronbach T, Fischer V, Meyer UA. Cyclosporine metabolism in human liver: identification of a cytochrome P-450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs. Clin Pharm Ther 1988;43:630-5.
6. 6. Thummel KE, Shen DD, Podoll TD, Kunze KL, Trager WF, Hartwell PS, et al. Use of midazolam as a human cytochrome P450 3A probe: in vitro-in vivo correlations in liver transplant patients. J Pharmacol Exp Ther 1994;271:549-56.
7. 7. Lindholm A, Henricsson S, Lind M, Dahlqvist R. Interindividual variability in the relative systemic availability of cyclosporine after oral dosing. Eur J Clin Pharmacol 1988;34:461-4.
8. 8. Lemaire M, Fahr A, Maurer G. Pharmacokinetics of cyclosporine: inter-and intra-individual variations and metabolic pathways. Transplant Proc 1990;22:1110-2.
9. 9. Daly AK. Molecular basis of polymorphic drug metabolism. J Mol Med 1995;73:539-53.
10. 10. Meyer UA, Zanger UM. Molecular mechanisms of genetic polymorphisms of drug metabolism. Annu Rev Pharmacol Toxicol 1997;37:269-96.
11. 11. Kleinbloesem CH, vam Brummelen P, Faber H, Danhof M, Vermeulen NPE, Breimer DD. Variability in nifedipine pharmacokinetics and dynamics: a new oxidation polymorphism in man. Biochem Pharmacol 1984;33:3721-4.
12. 12. Rebbeck TR, Jaffe JM, Walker AH, Wein AJ, Malkowicz SB. Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst 1998;90:1225-9.
13. 13. Felix CA, Walker AH, Lange BJ, William TM, Winick NJ, Cheung NKV, et al. Association of CYP3A4 genotype with treatment related leukemia. Proc Natl Acad Sci 1998;95:13176-81.
14. 14. Kinirons MT, Lang CC, He HB, Ghebreselasie K, Shay S, Robin DW, et al. Triazolam pharmacokinetics and pharmacodynamics in Caucasians and Southern Asians: ethnicity and CYP3A activity. Br J Clin Pharmacol 1996;41:69-72.
15. 15. Wood AJJ, Zhou HH. Ethnic differences in drug disposition and responsiveness. Clin Pharmacokinet 1991;20:350-73.
16. 16. Ahsan CH, Renwick AG, Macklin B, Challenor VF, Waller DG, George CF. Ethnic differences in the pharmacokinetics of oral nifedipine. Br J Clin Pharmacol 1991;31:399-403.
17. 17. Ahsan CH, Renwick AG, Waller DG, Challenor VF, George CF, Amanullah M. The influence of dose and ethnic origins on the pharmacokinetics of nifedipine. Clin Pharmacol Ther 1993;54:329-38.
18. 18. Robbins AS, Whittemore AS, Van Den Eeden SK. Race, prostate cancer survival, and membership in a large health organization. J Natl Cancer Inst 1998;90:986-90.
19. 19. Merril RM, Brawley OW. Prostate cancer incidence and mortality rates among white and black men. Epidemiology 1997;8:126-31.
20. 20. Watkins PB. Noninvasive tests of CYP3A enzymes. Pharmacogenetics 1994;4:171-84.
21. 21. Turgeon DK, Leichtman AB, Blake DS, Schmouder RL, Lown KS, Annesley TM, et al. Prediction of interpatient and intrapatient variation in OG 37-325 dosing requirements by the erythromycin breath test. Transplantation 1994;57:1736-41.
22. 22. Schellens JH, van der Wart JH, Brugman M, Breimer DD. Influence of enzyme induction and inhibition on the oxidation of nifedipine, sparteine, mephenytoin and antipyrine in humans as assessed by the "cocktail" study design. J Pharm Exp Ther 1989;249:638-45.
23. 14C N-methyl] erythromycin breath test in healthy volunteers. J Clin Pharmacol 1998;38:492-5.
24. 24. Hashimoto H, Toide K, Kitamura R, Fujita M, Tagawa S, Itoh S, et al. Gene structure of CYP3A4, an adult-specific form of cytochrome P450 in human livers, and its transcriptional control. Eur J Biochem 1993;218:585-95.
25. 25. Kolars JC, Lown KS, Schmiedlin-Ren P, Ghosh M, Fang C, Wrighton SA, et al. CYP3A gene expression in human gut epithelium. Pharmacogenetics 1994;4:247-59.
26. 26. Kolars JC, Schmiedlin-Ren P, Schuetz JD, Fang C, Watkins PB. Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. J Clin Invest 1992;90:1871-8.
27. 27. Lown KS, Ghosh M, Watkins PB. Sequences of intestinal and hepatic cytochrome P450 3A4 cDNAs are identical. Drug Metab Dispos 26 1998;26:185-7.
28. 28. Inoue K, Yamazaki H, Imiya K, Akasaka S, Guengerich FP, Shimada T. Relationship between CYP2C9 and CYP2C19 genotypes and tolbutamide methyl hydroxylation and S-mephenytoin 4′-hydroxylation activities in livers of Japanese and Caucasian populations. Pharmacogenetics 1997;7:103-13.
29. 29. Flaws JA, Bush TL. Racial differences in drug metabolism: an explanation for the higher breast cancer mortality in blacks? Med Hypotheses 1998;50:327-9.
30. 30. Hong JY, Yang CS. Genetic polymorphism of cytochrome P450 as a biomarker of susceptibility to environmental toxicity. Environ Health Perspect 1997;105:759-62.
31. 31. Wilkinson GR. Cytochrome P4503A (CYP3A) metabolism: prediction of in vivo activity in humans. J Pharmacokinet Biopharm 1996;24:475-90.